Future experimentation in preclinical infection models will reveal the dose-dependent antiviral activity of IFNβ-ACE2 versus control proteins, and these experiments will reveal whether ACE2-mediated targeting alone or in combination with ACE2-mediated neutralization represents the dominant therapeutic mechanism in vivo. This evidence concerns the gene ACE2 and infection.